GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59

GSK GSK and Pfizer PFE announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the expanded use of their respiratory syncytial virus (RSV) vaccines.The ACIP has now recommended the use of GSK’s RSV vaccine, Arexvy, and PFE’s RSV vaccine, Abrysvo, in adults aged 50-59 who are at high risk of severe RSV disease. Individuals with underlying medical conditions like obesity, cardiovascular disease, diabetes, chronic obstructive pulmonary disorder (COPD), asthma and other chronic illnesses are at increased risk of RSV disease.The updated ACIP recommendation expands the committee’s previous vote issued last June, which recommended the use of RSV vaccines for all adults aged 75 years. However, for those aged between 60 and 74, the ACIP recommended the vaccines for individuals at a higher risk of severe RSV disease due to underlying medical conditions.The updated ACIP recommendation lowers the recommended age for RSV vaccination from 60 to 50 for high-risk adults.The ACIP’s recommendation is pending final approval by the director of the CDC and the Department of Health and Human Services.GSK's Price PerformanceYear to date, shares of GSK have increased 4.6% against the industry’s decline of 6.6%.Image Source: Zacks Investment ResearchPFE's Price PerformanceYear to date, shares of Pfizer have decreased 16.9% compared with the industry’s decline of 5.4%.Image Source: Zacks Investment ResearchArexvy and Abrysvo are approved by the FDA for use in all individuals aged 60 and above. Arexvy is also approved for high-risk individuals aged 50-59, while Abrysvo is approved for high-risk adults aged 18-59 in the United States.GSK is currently conducting clinical studies on Arexvy for expanded use in adults aged 18 to 49 years.Arexvy generated sales worth £590 million in 2024, while Abrysvo generated sales worth $755 million. Sales of both Arexvy and Abrysvo were impacted last year, mainly due to the revised recommendations for RSV vaccinations issued by the ACIP in June 2024.Another vaccine maker, Moderna’s MRNA RSV vaccine – mResvia – was approved last year by the FDA and the European Commission to prevent RSV-LRTD in older adults aged 60 years and above.An FDA filing is currently under review, seeking the expanded use of Moderna’s vaccine in high-risk adults aged 18-59 years. A final decision is expected by June 12, 2025. MRNA is also working on expanding the vaccine’s use in pediatric populations.GSK & PFE's Zacks RankBoth GSK and Pfizer currently carry a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks